Bristol-Myers Squibb's (BMS) device sales rise 13% in third quarter
This article was originally published in Clinica
Bristol-Myers Squibb has seen a 13% increase in medical device sales in the third quarter. The company attributes this rise partly to the acquisition of Calgon Vestal Labs but also to continued growth in ostomy and woundcare products. The Nexgen knee replacement system, which was introduced in the first quarter, has experienced strong initial acceptance, says BMS.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.